Micro Therapeutics' balloon catheter:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared Micro Therapeutics' balloon catheter system for selectively stopping or controlling blood flow in small peripheral blood vessels. The Equinox occlusion balloon system can access tortuous anatomy and can stop blood flow to distal sites allowing vascular abnormalities to be embolised. The device, which will be used with the company's SilverSpeed hydrophilic guidewire, was released in Europe earlier this year where it will be distributed by Guidant. Irvine, California-based Micro Therapeutics will distribute the product in the US.
You may also be interested in...
PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
Biden Aims For 200 Mil. More COVID Vaccine Doses As Nervous Europe Eyes Its Borders
Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: